BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 30701671)

  • 1. Timing of brain metastases development in metastatic renal cell cancer patients treated with targeted therapies and survival outcomes: An Australian multicenter study.
    Ha FJ; Spain L; Dowling A; Kwan EM; Pezaro C; Day D; Chia PL; Tran B; Pook D; Weickhardt AJ
    Asia Pac J Clin Oncol; 2019 Oct; 15(5):e97-e102. PubMed ID: 30701671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Systemic Therapy in Metastatic Renal-Cell Carcinoma Patients With Synchronous and Metachronous Brain Metastases.
    Parmar A; Soliman H; Sahgal A; Bjarnason GA
    Clin Genitourin Cancer; 2020 Jun; 18(3):e224-e232. PubMed ID: 32139300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic Factors for Survival of Patients With Synchronous or Metachronous Brain Metastasis of Renal Cell Carcinoma.
    Choi SY; Yoo S; You D; Jeong IG; Song C; Hong B; Hong JH; Ahn H; Kim CS
    Clin Genitourin Cancer; 2017 Dec; 15(6):717-723. PubMed ID: 28552571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world Assessment of Clinical Outcomes in Patients with Metastatic Renal Cell Carcinoma with or Without Sarcomatoid Features Treated with First-line Systemic Therapies.
    Sawaya GB; Dragomir A; Wood LA; Kollmannsberger C; Basappa NS; Kapoor A; Soulières D; Finelli A; Heng DYC; Castonguay V; Canil C; Winquist E; Graham J; Bjarnason GA; Bhindi B; Lalani AK; Pouliot F; Breau RH; Saleh R; Tanguay S
    Eur Urol Oncol; 2024 Jun; 7(3):570-580. PubMed ID: 38097481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synchronous Versus Metachronous Metastatic Disease: Impact of Time to Metastasis on Patient Outcome-Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Donskov F; Xie W; Overby A; Wells JC; Fraccon AP; Sacco CS; Porta C; Stukalin I; Lee JL; Koutsoukos K; Yuasa T; Davis ID; Pezaro C; Kanesvaran R; Bjarnason GA; Sim HW; Rathi N; Kollmannsberger CK; Canil CM; Choueiri TK; Heng DYC
    Eur Urol Oncol; 2020 Aug; 3(4):530-539. PubMed ID: 32037304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival and prognostic factors of patients with renal cell cancer with bone metastasis in the era of targeted therapy: A single-institution analysis.
    Du Y; Pahernik S; Hadaschik B; Teber D; Duensing S; Jäger D; Hohenfellner M; Grüllich C
    Urol Oncol; 2016 Oct; 34(10):433.e1-8. PubMed ID: 27321354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved Survival Outcomes for Kidney Cancer Patients With Brain Metastases.
    Bowman IA; Bent A; Le T; Christie A; Wardak Z; Arriaga Y; Courtney K; Hammers H; Barnett S; Mickey B; Patel T; Whitworth T; Stojadinovic S; Hannan R; Nedzi L; Timmerman R; Brugarolas J
    Clin Genitourin Cancer; 2019 Apr; 17(2):e263-e272. PubMed ID: 30538068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic Treatments for Metastatic Renal Cell Carcinoma: 10-Year Experience of Immunotherapy and Targeted Therapy.
    Kim SH; Park WS; Kim SH; Joung JY; Seo HK; Lee KH; Chung J
    Cancer Res Treat; 2016 Jul; 48(3):1092-101. PubMed ID: 26875203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidemiology and survival outcomes of synchronous and metachronous brain metastases: a retrospective population-based study.
    Jiang K; Parker M; Materi J; Azad TD; Kamson DO; Kleinberg L; Ye X; Rincon-Torroella J; Bettegowda C
    Neurosurg Focus; 2023 Aug; 55(2):E3. PubMed ID: 37527669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncologic Outcomes of Cytoreductive Nephrectomy in Synchronous Metastatic Renal-Cell Carcinoma: A Single-Center Experience.
    Choi CI; Kang M; Sung HH; Jeon HG; Jeong BC; Jeon SS; Lee HM; Seo SIL
    Clin Genitourin Cancer; 2018 Dec; 16(6):e1189-e1199. PubMed ID: 30262447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overall survival in Swedish patients with renal cell carcinoma treated in the period 2002 to 2012: Update of the RENCOMP study with subgroup analysis of the synchronous metastatic and elderly populations.
    Lindskog M; Wahlgren T; Sandin R; Kowalski J; Jakobsson M; Lundstam S; Ljungberg B; Harmenberg U
    Urol Oncol; 2017 Sep; 35(9):541.e15-541.e22. PubMed ID: 28623071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival prognoses of Heng intermediate-risk patients with metastatic renal cell carcinoma treated with immunotherapy or targeted therapy: A real-world, single-center retrospective study.
    Kim SH; Lee DE; Joung JY; Seo HK; Lee KH; Chung J
    Investig Clin Urol; 2020 Mar; 61(2):146-157. PubMed ID: 32158965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival of patients receiving systematic therapy for metachronous or synchronous metastatic renal cell carcinoma: a retrospective analysis.
    Kim SH; Lee DE; Park B; Joo J; Joung JY; Seo HK; Lee KH; Chung J
    BMC Cancer; 2019 Jul; 19(1):688. PubMed ID: 31307432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic effect of cytoreductive nephrectomy in synchronous metastatic renal cell carcinoma: a comparative study using inverse probability of treatment weighting.
    Klatte T; Fife K; Welsh SJ; Sachdeva M; Armitage JN; 'Aho T; Riddick AC; Matakidou A; Eisen T; Stewart GD
    World J Urol; 2018 Mar; 36(3):417-425. PubMed ID: 29256020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does the onset of bone metastasis in sunitinib-treated renal cell carcinoma patients impact the overall survival?
    Ivanyi P; Koenig J; Trummer A; Busch JF; Seidel C; Reuter CW; Ganser A; Grünwald V
    World J Urol; 2016 Jul; 34(7):909-15. PubMed ID: 26586475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Impact of Pancreatic Metastases from Renal Cell Carcinoma: A Multicenter Retrospective Analysis.
    Grassi P; Doucet L; Giglione P; Grünwald V; Melichar B; Galli L; De Giorgi U; Sabbatini R; Ortega C; Santoni M; Bamias A; Verzoni E; Derosa L; Studentova H; Pacifici M; Coppa J; Mazzaferro V; de Braud F; Porta C; Escudier B; Procopio G
    PLoS One; 2016; 11(4):e0151662. PubMed ID: 27064898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Heng DY; Wells JC; Rini BI; Beuselinck B; Lee JL; Knox JJ; Bjarnason GA; Pal SK; Kollmannsberger CK; Yuasa T; Srinivas S; Donskov F; Bamias A; Wood LA; Ernst DS; Agarwal N; Vaishampayan UN; Rha SY; Kim JJ; Choueiri TK
    Eur Urol; 2014 Oct; 66(4):704-10. PubMed ID: 24931622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extracerebral metastases determine the outcome of patients with brain metastases from renal cell carcinoma.
    Vogl UM; Bojic M; Lamm W; Frischer JM; Pichelmayer O; Kramer G; Haitel A; Kitz K; Harmankaya K; Zielinski CC; Schmidinger M
    BMC Cancer; 2010 Sep; 10():480. PubMed ID: 20819239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluating the impact of early identification of asymptomatic brain metastases in metastatic renal cell carcinoma.
    Parmar A; Ghosh S; Sahgal A; Lalani AA; Hansen AR; Reaume MN; Wood L; Basappa NS; Heng DYC; Graham J; Kollmannsberger C; Soulières D; Breau RH; Tanguay S; Kapoor A; Pouliot F; Bjarnason GA
    Cancer Rep (Hoboken); 2023 Mar; 6(3):e1763. PubMed ID: 36517084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence and Outcomes of Delayed Targeted Therapy After Cytoreductive Nephrectomy for Metastatic Renal-Cell Carcinoma: A Nationwide Cancer Registry Study.
    Woldu SL; Matulay JT; Clinton TN; Singla N; Freifeld Y; Sanli O; Krabbe LM; Hutchinson RC; Lotan Y; Hammers H; Hannan R; Brugarolas J; Bagrodia A; Margulis V
    Clin Genitourin Cancer; 2018 Dec; 16(6):e1221-e1235. PubMed ID: 30217763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.